Century Therapeutics (IPSC) Set to Announce Quarterly Earnings on Thursday

Century Therapeutics (NASDAQ:IPSC) is projected to release its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $1.63 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 17, 2026 at 9:30 AM ET.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). On average, analysts expect Century Therapeutics to post ($0.51) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

Century Therapeutics Price Performance

Century Therapeutics stock opened at $1.81 on Tuesday. Century Therapeutics has a 12-month low of $0.43 and a 12-month high of $3.04. The stock has a market capitalization of $327.74 million, a P/E ratio of -1.95 and a beta of 1.78. The firm’s 50-day moving average is $1.68 and its two-hundred day moving average is $2.08.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IPSC. Weiss Ratings reissued a “sell (d-)” rating on shares of Century Therapeutics in a research report on Tuesday, September 29th. Wall Street Zen lowered shares of Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Century Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $4.75.

About Century Therapeutics

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.

Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.